Oct 29, 2018
MediSieve Head of R&D as a Royal Academy of Engineering's SME Leader
Dr Cristina Blanco Andujar, the Head of R&D at the innovative medical device company, MediSieve, has been awarded a position on the Royal Academy of Engineering's prestigious SME Leaders Programme.
LONDON – October 29, 2022 – The SME Leaders Programme will support leaders of promise within high growth SMEs in the engineering sector. The programme will develop their leadership skills via training courses and executive education, as well as masterclasses and workshops delivered by senior business leaders.
Dr Blanco has been at the fulcrum in the rapid rise of MediSieve, the medical device company which has made great strides in magnetic blood filtration technology. She is a world expert in the development and conjugation of magnetic particles, and leads the company’s R&D team as they develop their products for malaria, leukaemia and sepsis.
Dr George Frodsham, founder and CEO of MediSieve, said: "We are delighted that Cristina has been chosen to take part in this hugely important programme, which is capable of shaping the future of engineering in this country. As a young company ourselves, we understand just how it is important to have the leadership skills to supplement the knowledge which we have as medical engineers, in order to succeed in business. Cristina is managing a rapidly growing team. We are excited at the opportunity for her to further increase her leadership and management skills and look forward to incorporating what she learns. We would like to thank the RAE and wish them every success with their SME Leaders Programme."
The Royal Academy of Engineering (RAE) offers an Enterprise Hub, which provides up and coming engineering leaders with an experienced personal mentor to guide them, including one on one coaching sessions. Those chosen to take part in the programme will also have the advantage of the Taylor Centre office space operated by the RAE, as well as the 'golden ticket' of a grant up to £10,000, which will go towards training and education expenses.
Through the programme, it is anticipated that engineering start-ups and SMEs in the UK can be better led, thanks to the improvement of leadership skills, with the end result being beneficial to the wider engineering sector in the UK. Participants are selected based on both individual and company potential; Dr Blanco and MediSieve were selected ahead of a number of other high quality candidates.
About Magnetic Blood Filtration
MediSieve's Magnetic Blood Filtration Platform is intended to enable the rapid and specific depletion of specific agents from the bloodstream of patients. The extracorporeal therapy uses therapeutic Magnetic Beads that are designed to bind specifically to the clinical target. The Beads are introduced into the extracorporeal circuit during the therapy, mixing with the patient’s blood and binding to the clinical targets. The Delivery Platform captures all the Magnetic Beads and bound targets, preventing their return to the patient.
About MediSieve
MediSieve is a London-based BioTech start-up that has developed Magnetic Blood Filtration, a revolutionary platform therapy that enables the physical removal of specific substances from the bloodstream of patients. It can be used (1) as a direct treatment, (2) to increase the safety and efficacy of other therapies, or (3) to enable personalised medicine. The company is a spin-off from University College London and is developing its products at the White City Innovation District in West London. MediSieve is actively seeking investment and partnerships.
MEDIA CONTACT:
Alina Kagermazova
INVESTOR AND PARTNERSHIP CONTACT:
George Frodsham
